Loxapine (Adasuve) vs Olanzapine (Zyprexa)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical and partners
NCT00628589 · Phase 3 · completed
The trial randomly assigned 344 participants to inhaled loxapine 5 mg, loxapine 10 mg, or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical agitation measure was significantly improved with both loxapine doses compared with placebo (p=0.0004 and p<0.0001).
Reported efficacy
Change in PANSS-EC From Baseline (Baseline and 2 hours): Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92) (met)
Result source: NCT00628589
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT03510325 · Phase 3 · completed
This trial randomly assigned 762 people with schizophrenia to active antipsychotic treatments, with outcomes rated by masked assessors but treatment assignment itself not blinded. Among 111 participants who had not responded to first-line treatment and were reassigned to a second drug, 31.7% responded on olanzapine against 44.7% on amisulpride and 62.5% on clozapine, a significant difference across the three (p=0.03). Olanzapine was the least effective of the second-line options tested.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
Reported efficacy
Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 (missed)
Result source: NCT03510325
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Loxapine (Adasuve) | Olanzapine (Zyprexa) |
|---|---|---|
| PANSS total, change | —Not reported | -8.8 vs 4.5−13.3 vs placeboNCT00686998 |
| CGI-S, change | —Not reported | —Not posted · NCT00083668 |
| PANSS response | —Not reported | 31.7% vs 44.7%avs amisulprideNCT03510325 |
| PSP, change | —Not reported | —Not posted · NCT00083668 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT00083668 |
PANSS total, change
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa)
- -8.8 vs 4.5−13.3 vs placeboNCT00686998
CGI-S, change
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
PANSS response
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa)
- 31.7% vs 44.7%avs amisulprideNCT03510325
PSP, change
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
Relapse (% of patients)
- Loxapine (Adasuve)
- —Not reported
- Olanzapine (Zyprexa)
- —Not posted · NCT00083668
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Loxapine (Adasuve): 4 of 5 rows · Olanzapine (Zyprexa): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Loxapine (Adasuve) | Olanzapine (Zyprexa) |
|---|---|---|
| PANSS-EC absolute change · score | -8.6 vs -5.5 placebo score @ 0.0119wk10 mga,b,c NCT00628589 · Phase 3 · monotherapy show 1 more dose-8.1 vs -5.5 placebo score @ 0.0119wk5 mg NCT00628589 · Phase 3 · monotherapy | -10.2 vs -9.9 IM Haloperidol Plus Lorazepam score @ 0.0119wkb,c NCT00797277 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 2.7%10 mgd NCT00628589 · Phase 3 · monotherapy show 8 more results1.7%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence | 63.4%Olanzapine/Intense Behavioral Weigd NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results55.9%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 38.2% NCT00190749 · Phase 4 · registry result, not featured evidence 60.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence 22%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 34.2%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 31.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 18.2% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | —10 mgd NCT00628589 · Phase 3 · monotherapy show 8 more results—5 mg NCT00628589 · Phase 3 · monotherapy —10 mg NCT00369577 · Phase 2 · registry result, not featured evidence —5 mg NCT00369577 · Phase 2 · registry result, not featured evidence —10 mg NCT00444028 · Phase 1 · registry result, not featured evidence —5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence —1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence —0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence | 14.9%Olanzapine/Intense Behavioral Weigd NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results18.6%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 0% NCT00190749 · Phase 4 · registry result, not featured evidence 8.3% NCT00088465 · Phase 3 · registry result, not featured evidence — NCT00797277 · Phase 3 · registry result, not featured evidence 4%Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence 10.5%Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination 5.5%Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 4.5% NCT00686998 · Phase 2 · registry result, not featured evidence —Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence —Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence —3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination —Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Serious AEs | 0.9%10 mgd NCT00628589 · Phase 3 · monotherapy show 8 more results0%5 mg NCT00628589 · Phase 3 · monotherapy 2.4%10 mg NCT00369577 · Phase 2 · registry result, not featured evidence 2.2%5 mg NCT00369577 · Phase 2 · registry result, not featured evidence 0%10 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%1.25 mg NCT00444028 · Phase 1 · registry result, not featured evidence 0%0.625 mg NCT00444028 · Phase 1 · registry result, not featured evidence | 19.8%Olanzapine/Intense Behavioral Weigd NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more results12.7%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT00190749 · Phase 4 · registry result, not featured evidence 18.3% NCT00088465 · Phase 3 · registry result, not featured evidence 0% NCT00797277 · Phase 3 · registry result, not featured evidence —Olanzapine NCT00401973 · Phase 3 · registry result, not featured evidence —Olanzapine + Amantadine NCT00401973 · Phase 3 · registry result, not featured evidence · combination —Olanzapine + Metformin NCT00401973 · Phase 3 · registry result, not featured evidence · combination 0% NCT00686998 · Phase 2 · registry result, not featured evidence 0%Cohort 1: Olanzapine (Fast-D) NCT06319170 · Phase 1 · registry result, not featured evidence 3.2%Cohort 2: Olanzapine (To-be-market NCT06319170 · Phase 1 · registry result, not featured evidence 0%Cohort 3: Olanzapine (Slow-C) NCT06319170 · Phase 1 · registry result, not featured evidence 0%3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 25%0.3 mg NCT00512070 · Phase na · registry result, not featured evidence · combination 5.9%Olanzapine Only NCT00512070 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 10 mgd dizziness 10.6% (placebo 9.6%) dysgeusia 10.6% (placebo 2.6%) sedation 10.6% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy show 8 more results5 mg sedation 12.9% (placebo 9.6%) dysgeusia 8.6% (placebo 2.6%) dizziness 5.2% (placebo 9.6%) NCT00628589 · Phase 3 · monotherapy 10 mg sedation 22% (placebo 14%) dysgeusia 17.1% (placebo 9.3%) headache 12.2% (placebo 2.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 5 mg sedation 13.3% (placebo 14%) dizziness 11.1% (placebo 9.3%) dysgeusia 4.4% (placebo 9.3%) NCT00369577 · Phase 2 · registry result, not featured evidence 10 mg dizziness 75% (placebo 35.7%) dysgeusia 75% (placebo 0%) somnolence 75% (placebo 21.4%) NCT00444028 · Phase 1 · registry result, not featured evidence 5 mg dizziness 57.1% (placebo 35.7%) fatigue 42.9% (placebo 7.1%) dysgeusia 28.6% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 2.5 mg dizziness 50% (placebo 35.7%) nausea 50% (placebo 0%) dysgeusia 33.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence 1.25 mg dizziness 25% (placebo 35.7%) dysgeusia 25% (placebo 0%) headache 25% (placebo 14.3%) NCT00444028 · Phase 1 · registry result, not featured evidence 0.625 mg dizziness 28.6% (placebo 35.7%) disturbance in attention 14.3% (placebo 7.1%) dysgeusia 14.3% (placebo 0%) NCT00444028 · Phase 1 · registry result, not featured evidence | d somnolence 23.8% weight increased 20.8% headache 19.8% NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 14 more resultsweight increased 30.4% headache 18.6% somnolence 18.6% NCT00982020 · Phase 4 · registry result, not featured evidence · combination weight increased 16.2% headache 10.3% sedation 10.3% NCT00190749 · Phase 4 · registry result, not featured evidence weight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence insomnia 10% somnolence 8% increased appetite 6% NCT00401973 · Phase 3 · registry result, not featured evidence somnolence 6.6% dry mouth 5.3% insomnia 5.3% NCT00401973 · Phase 3 · registry result, not featured evidence · combination diarrhoea 13.7% somnolence 11% nausea 6.8% NCT00401973 · Phase 3 · registry result, not featured evidence · combination weight increased 40.9% (placebo 0%) increased appetite 18.2% (placebo 2.4%) somnolence 18.2% (placebo 2.4%) NCT00686998 · Phase 2 · registry result, not featured evidence injection site irritation 6.9% injection site pain 6.9% psychotic disorder 6.9% NCT06319170 · Phase 1 · registry result, not featured evidence injection site pain 9.7% somnolence 9.7% blood creatine phosphokinase increased 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence alanine aminotransferase increased 6.5% aspartate aminotransferase increased 6.5% somnolence 6.5% NCT06319170 · Phase 1 · registry result, not featured evidence 3 mg abnormal lab values 33.3% decreased appetite 16.7% depression 16.7% NCT00512070 · Phase na · registry result, not featured evidence · combination 0.3 mg abnormal lab values 50% depression 25% psychotic symptoms 25% NCT00512070 · Phase na · registry result, not featured evidence · combination abnormal lab values 29.4% insomnia/sleep disturbance 23.5% diarrhea 17.6% NCT00512070 · Phase na · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Loxapine (Adasuve)
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Olanzapine (Zyprexa)
show 3 more results
show 1 more result
show 1 more result
show 2 more results
show 1 more result
+ 15 further endpoints in the CSV export.
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Loxapine (Adasuve)
Marketed by Lee's Pharmaceutical and partners
NCT04148963 · Phase 3 · status unknown
This Phase 3 trial randomly assigned agitated adults with schizophrenia or bipolar disorder to inhaled loxapine or inhaled placebo under quadruple-blind conditions, using change in the PANSS-EC agitation scale at 2 hours as the primary endpoint. No results have been posted, so this remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
No aligned efficacy figure on record for this race.
Olanzapine (Zyprexa)
Marketed by Cheplapharm Arzneimittel GmbH and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Loxapine (Adasuve): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa)
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Available safety results
Olanzapine (Zyprexa)
| Dropout rate | 63.4%Olanzapine/Intense Behavioral Weig NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more result55.9%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | 14.9%Olanzapine/Intense Behavioral Weig NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more result18.6%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
| Serious AEs | 19.8%Olanzapine/Intense Behavioral Weig NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more result12.7%Olanzapine/Standard Behavioral Wei NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
| Most frequent reported AEs | somnolence 23.8% weight increased 20.8% headache 19.8% NCT00982020 · Phase 4 · registry result, not featured evidence · combination show 1 more resultweight increased 30.4% headache 18.6% somnolence 18.6% NCT00982020 · Phase 4 · registry result, not featured evidence · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Loxapine (Adasuve)'s landscape · Olanzapine (Zyprexa)'s landscape